Biohaven’s Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

cagkansayin Biohaven: Navigating Through Biotech’s Competitive Landscape Biohaven’s (NYSE:BHVN) stock is up 130% since my “Sell” recommendation back in August. In hindsight, my analysis missed the mark, and it appears I was too focused on their lead program (troriluzole) and overlooked their early-stage assets like BHV-7000. Fortunately, selling’s only downside is opportunity cost and, due…

Read More

Week Ahead: Attention Turns Back To Inflation

Dilok Klaisataporn The terribly mixed US jobs report spurred dramatic intraday swings in exchange and US interest rates. But at the close, the dollar was little changed against most major currencies, and expectations for Fed policy was nearly unchanged. The futures market has about a 70% chance of a cut at the March meeting. The…

Read More

Farfetch Turns From Richemont Blessing To Curse

Pascal Le Segretain By Breakingviews For Compagnie Financiere Richemont, not all that glitters is gold. The $65 billion owner of jeweler Cartier finally agreed to sell a portion of its struggling digital arm, Yoox Net-A-Porter, to high-end online marketplace Farfetch in August 2022. At the time, it looked like a savvy fix. But now, Farfetch’s…

Read More